 Patient will receive a single treatment consisting of conditioning chemotherapy for seven days cyclophosphamide for two days and fludarabine for five days, intravenous infusion of high number of in vitro expanded tumor infiltrating lymphocytes followed by two weeks with daily low-dose interleukine-2. Patients will be evaluated for toxicity and immune response. 